BY OUR PLATFORMS
BY THERAPEUTIC AREA
01 April 2021 - 31 March 2024
Start – End dates: 01/04/21 – 31/03/24
Project reference: E!114899
Total budget: 3,349,547.88€
Co-financed by: Eurostars, Eureka EU & CDTI, Spain
Partners: Life Science Methods (Países Bajos), Confocal.nl (Países Bajos), Bioreperia (Suecia), Center for Molecular Medicine Norway (Norway)
Over 10.000 compounds are screened for each approaved drug as it is still very difficult to predict the safety and efficacy of a drug candidate early in the drug discovery process. Zebrafish zenograft models are a promisisng solution, because they are small, inexpensive to keep and larvae are easy to manipualte and transparent, enabling screening of compunds on human tumours in context of a living organism. However, uptake is limited due to labour intensive workflows.
The ROBO-FISH consortium will develop and validate injection and imaging robots to automate oncology drug screening in zebrafish to mimic human disease. The robots will optimize sample handling and automate organ-specific injection and imaging, enabling high-throughput drug screening with zebrafish larvae. After the project, the validated ROBO-FISH workflow (injection robot and imaging robot) will be implemented at the Centre for Molecular Medicine Norway and CROs ZeClinics and BioReperia.
Please leave your details in the form below.